C. O'Brian

J. Murray, J. M. Hudson, J. Wharton, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Biology of the protein kinase C family

N. Ward, C. O'Brian, C. O'brian, 1989, Cancer and Metastasis Reviews.

Studies on protein kinase C and colon carcinogenesis.

J. Guillem, I. Weinstein, K. Forde, 1987, Archives of surgery.

Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells.

C. O'Brian, Jubilee R Stewart, Catherine A O'Brian, 2005, Molecular cancer therapeutics.

Structural and functional studies of protein kinase C.

I. Weinstein, M. Johnson, C. O'Brian, 1988, Advances in experimental medicine and biology.

N-myristyl-Lys-Arg-Thr-Leu-Arg: a novel protein kinase C inhibitor.

R. Liskamp, J. V. van Boom, N. Ward, 1990, Biochemical pharmacology.

Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5‐fluorouracil

C. Bucana, I. Fidler, D. Fan, 1992, International journal of cancer.

Triphenylethylenes: a new class of protein kinase C inhibitors.

I. Weinstein, R. Liskamp, D. Solomon, 1986, Journal of the National Cancer Institute.

Role of protein kinase C in regulation of gene expression and relevance to tumor promotion.

I. Weinstein, P. Kirschmeier, M. Johnson, 1987, Environmental health perspectives.

Binding of protein kinase C to napthalenesulfonamide- and phenothiazine-agarose columns: evidence for direct interactions between protein kinase C and cationic amphiphilic inhibitors of the enzyme.

I. Weinstein, C. O'Brian, G. Housey, 1987, Biochemical pharmacology.

Partial Reversal of Multidrug Resistance in Human Breast Cancer Cells by an N-Myristoylated Protein Kinase C- Pseudosubstrate Peptide (*)

P. Bergman, N. Ward, C. O'Brian, 1996, The Journal of Biological Chemistry.

The Contribution of Protein Kinase C to Multiple Drug Resistance in Cancer

N. Ward, C. O'Brian, K. Gupta, 1995 .

Irreversible inactivation of protein kinase C isozymes by thiol-reactive peptide substrate analogs.

N. Ward, C. O'Brian, J. Stewart, 2003, Methods in molecular biology.

Covalent Modification of Protein Kinase C Isozymes by the Inactivating Peptide Substrate Analog N-Biotinyl-Arg-Arg-Arg-Cys-Leu-Arg-Arg-Leu

N. Ward, C. O'Brian, K. R. Gravitt, 1996, The Journal of Biological Chemistry.

Inhibition of protein kinase C by melittin: antagonism of binding interactions between melittin and the catalytic domain by active-site binding of MgATP.

N. Ward, C. O'Brian, K. R. Gravitt, 1994, Biochemical pharmacology.

Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant small cell lung cancer line.

J. Wharton, N. Restifo, B. Glisson, 1994, Lymphokine and cytokine research.

An N-myristoylated protein kinase C-α pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate

P. Bergman, C. O'Brian, K. R. Gravitt, 1997, Cancer Chemotherapy and Pharmacology.

ReviewPost-translational disulfide modifications in cell signaling—role of inter-protein, intra-protein, S-glutathionyl, and S-cysteaminyl disulfide modifications in signal transmission

C. O'Brian, F. Chu, C. O'brian, 2005, Free radical research.

Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme.

N. Ward, C. O'Brian, B. Anderson, 1988, Journal of the National Cancer Institute.

The role of protein kinase C in multidrug resistance.

D. Fan, N. Ward, C. O'Brian, 1994, Cancer treatment and research.

Characterization of a Ca2(+)- and phospholipid-dependent ATPase reaction catalyzed by rat brain protein kinase C.

N. Ward, C. O'Brian, C. O'brian, 1990, Biochemistry.

Inhibition of protein kinase C and calmodulin by the geometric isomers cis‐ and trans‐tamoxifen

R. Liskamp, C. Ioannides, N. Ward, 1990, Biopolymers.

Inhibition of protein kinase C by the 12-O-tetradecanoylphorbol-13-acetate antagonist glycyrrhetic acid.

V. Vogel, N. Ward, C. O'Brian, 1990, Cancer letters.

Regulation of protein kinase C isozyme activity by S-glutathiolation.

N. Ward, C. O'Brian, F. Chu, 2002, Methods in enzymology.

Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity

J. Murray, A. Kudelka, D. Gershenson, 2004, Molecular and Cellular Biochemistry.

Altered Signal Transduction in Carcinogenesis1

N. Ward, C. O'Brian, Constantin G. Loannides, 1993 .

Induction of Tumor-Reactive CTL by C-Side Chain Variants of the CTL Epitope HER-2/neu Protooncogene (369-377) Selected by Molecular Modeling of the Peptide: HLA-A2 Complex1

J. Murray, D. Carter, A. Kudelka, 2002, The Journal of Immunology.

Resveratrol Antagonizes EGFR-Dependent Erk1/2 Activation in Human Androgen-Independent Prostate Cancer Cells with Associated Isozyme-Selective PKCα Inhibition

C. O'Brian, J. Stewart, C. O'brian, 2004, Investigational New Drugs.

Elevated protein kinase C expression in human breast tumor biopsies relative to normal breast tissue.

S. Singletary, V. Vogel, N. Ward, 1989, Cancer research.

N‐α‐Tosyl‐L‐lysine chloromethyl ketone and N‐α‐tosyl‐L‐phenylalanine chloromethyl ketone inhibit protein kinase C

D. Solomon, C. O'Brian, I. Bernard Weinstein, 1985 .

Protein kinase C phosphorylates the synthetic peptide Arg-Arg-Lys-Ala-Ser-Gly-Pro-Pro-Val in the presence of phospholipid plus either Ca2+ or a phorbol ester tumor promoter.

D. Lawrence, I. Weinstein, E. Kaiser, 1984, Biochemical and biophysical research communications.

Oxidant-induced S-glutathiolation inactivates protein kinase C-alpha (PKC-alpha): a potential mechanism of PKC isozyme regulation.

C. Ioannides, N. Ward, C. O'Brian, 2000, Biochemistry.

Isolation of cDNA clones encoding protein kinase C: evidence for a protein kinase C-related gene family.

I. Weinstein, P. Kirschmeier, M. Johnson, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Molecular Targets of Resveratrol: Implications to Health and Disease Prevention

C. O'Brian, F. Chu, C. O'brian, 2005 .

Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation.

K. Christman, C. O'Brian, J. Stewart, 2000, Biochemical pharmacology.

A peptide substrate-based affinity label blocks protein kinase C-catalyzed ATP hydrolysis and peptide-substrate phosphorylation.

N. Ward, C. O'Brian, J. Stewart, 1999, Archives of biochemistry and biophysics.

NMR studies of the backbone protons and secondary structure of pentapeptide and heptapeptide substrates bound to bovine heart protein kinase.

P. Rosevear, A. Mildvan, D. Fry, 1984, Biochemistry.

Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue.

I. Weinstein, C. O'Brian, G. Housey, 1988, Cancer research.

Cancer Chemoprotective Activity of Stilbenes: Resveratrol

C. O'Brian, J. Stewart, F. Chu, 2005 .

Induction of transformation progression in type 5 adenovirus-transformed rat embryo cells by a cloned protein kinase C beta 1 gene and reversal of progression by 5-azacytidine.

Z. Su, P. Fisher, R. Shen, 1994, Oncogene.

Irreversible Inactivation of Protein Kinase C by a Peptide-Substrate Analog (*)

N. Ward, C. O'Brian, K. R. Gravitt, 1995, The Journal of Biological Chemistry.

Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein‐tyrosine kinase activity

I. Fidler, Z. Dong, C. O'Brian, 1993, Journal of leukocyte biology.

Activation of rat brain protein kinase C by lipid oxidation products.

L. Marnett, I. Weinstein, A. Bull, 1988, Biochemical and biophysical research communications.

Identification of an Inactivating Cysteine Switch in Protein Kinase Cε, a Rational Target for the Design of Protein Kinase Cε–Inhibitory Cancer Therapeutics

R. Kobayashi, J. Koomen, C. O'Brian, 2005 .

Protein kinase CA mediates epidermal growth factor receptor transactivation in human prostate cancer cells

C. O'Brian, J. Stewart, C. O'brian, 2005 .

Inhibition of protein kinase C by a synthetic peptide corresponding to cytoplasmic domain residues 828-848 of the human immunodeficiency virus type 1 envelope glycoprotein.

N. Ward, C. O'Brian, K. R. Gravitt, 1995, Cancer letters.

Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism

P. Bergman, N. Ward, C. O'Brian, 2004, Investigational New Drugs.

Level of protein kinase C activity correlates directly with resistance to adriamycin in murine fibrosarcoma cells

I. Fidler, C. Seid, D. Fan, 1989, FEBS letters.

N-alpha-Tosyl-L-lysine chloromethyl ketone and N-alpha-tosyl-L-phenylalanine chloromethyl ketone inhibit protein kinase C.

I. Weinstein, D. Solomon, C. O'Brian, 1985, FEBS letters.